TrialBlood advances2020

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

Genmin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.